Sickle Cell
Conditions
Interventions
This study will be an experimental clinical trial with two parallel groups: a control group (CG) and a treatment group (TG), each composed of 10 participants (n=10 per group). Participants will be ran
allocation to the groups. The control group (CG) will receive exclusively the standard conventional treatment established for the clinical condition under study, according to current care protocols. T
Sponsors
Instituto Multidisciplinar em Saúde da Universidade Federal da Bahia - Campus Anísio Teixeira
Universidade Federal da Bahia
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Individuals aged 18 years or older; weighing 40 kilograms or more; of both sexes; female and malepatients under professional care for sickle cell disease; and individuals who express consent to participate in the research by signing the informed consent form
Exclusion criteria
Exclusion criteria: Pregnant women; alterations in coagulation factors, hemophilia, thrombocytopenia, etc.; hemorrhages, glaucoma, thyroid disorders, hyper- and hypothyroidism or nodules; neoplasms, history of photosensitivity, history of hemorrhagic stroke, and finally, patients with continuous use of opioid analgesics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effectiveness of an adjuvant treatment protocol with low-intensity laser for vascular photobiomodulation (VPM), using red laser at a wavelength of 660 nm, with a power of 100 mW, in pain management and modulation of hematological and blood rheological factors in black patients with Sickle Cell Disease in the southwest region of Bahia | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the socioeconomic, demographic, clinical, and epidemiological characteristics of patients with Sickle Cell Disease (SCD);To evaluate the effectiveness of pain control through treatment with FBMV in patients with DF using the VAS and McGill scales;To monitor changes in vital signs such as mean arterial pressure (MAP), heart rate (HR), respiratory rate, and oxygen saturation (SpO2) in patients with sickle cell disease (SCD) caused by treatment with FBMV;To evaluate the hematological changes, including the parameters of the red blood cell count, white blood cell count, platelet count, and hematimetric indices, promoted by treatment with FBMV | — |
Countries
BR
Contacts
Public ContactLuciano Rosa
Universidade Federal da Bahia
Outcome results
None listed